ZA201505768B - Respirable agglomerates of porous carrier particles and micronized drug - Google Patents

Respirable agglomerates of porous carrier particles and micronized drug

Info

Publication number
ZA201505768B
ZA201505768B ZA2015/05768A ZA201505768A ZA201505768B ZA 201505768 B ZA201505768 B ZA 201505768B ZA 2015/05768 A ZA2015/05768 A ZA 2015/05768A ZA 201505768 A ZA201505768 A ZA 201505768A ZA 201505768 B ZA201505768 B ZA 201505768B
Authority
ZA
South Africa
Prior art keywords
carrier particles
porous carrier
micronized drug
respirable agglomerates
respirable
Prior art date
Application number
ZA2015/05768A
Other languages
English (en)
Inventor
Jeffry Weers
Patrick Teung
Thomas Tarara
Michael Hartman
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ZA201505768B publication Critical patent/ZA201505768B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2015/05768A 2013-03-14 2015-08-11 Respirable agglomerates of porous carrier particles and micronized drug ZA201505768B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361784842P 2013-03-14 2013-03-14
PCT/IB2014/059739 WO2014141135A1 (en) 2013-03-14 2014-03-13 Respirable agglomerates of porous carrier particles and micronized drug

Publications (1)

Publication Number Publication Date
ZA201505768B true ZA201505768B (en) 2017-03-29

Family

ID=50478894

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2015/05768A ZA201505768B (en) 2013-03-14 2015-08-11 Respirable agglomerates of porous carrier particles and micronized drug

Country Status (22)

Country Link
US (2) US9452139B2 (enExample)
EP (1) EP2968570A1 (enExample)
JP (1) JP6374414B2 (enExample)
KR (1) KR20150129716A (enExample)
CN (1) CN105188757B (enExample)
AU (2) AU2014229265A1 (enExample)
BR (1) BR112015021814A2 (enExample)
CA (1) CA2905615A1 (enExample)
CL (1) CL2015002632A1 (enExample)
EA (1) EA201591729A1 (enExample)
GT (1) GT201500295A (enExample)
HK (1) HK1212616A1 (enExample)
IL (1) IL240963A (enExample)
MA (1) MA38397A1 (enExample)
MX (1) MX2015012814A (enExample)
PE (1) PE20151655A1 (enExample)
PH (1) PH12015501882A1 (enExample)
SA (1) SA515361055B1 (enExample)
SG (1) SG11201506397QA (enExample)
TN (1) TN2015000395A1 (enExample)
WO (1) WO2014141135A1 (enExample)
ZA (1) ZA201505768B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT1993360T (lt) 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明(cyclopamine)類似物類
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
RU2569678C2 (ru) 2010-04-22 2015-11-27 Вертекс Фармасьютикалз Инкорпорейтед Способ получения циклоалкилкарбоксамидо-индольных соединений
BR112015018121A2 (pt) * 2013-01-31 2017-07-18 Prosonix Ltd composição para terapia por inalação, composição farmacêutica, inalador de pó seco, inalador pressurizado dosimetrado ou inalador nasal ativado por respiração, método de tratar uma doença ou distúrbio respiratório ou uma doença ou distúrbio pulmonar em um paciente, e, método de preparar composições ou inaladores
US9452139B2 (en) * 2013-03-14 2016-09-27 Novartis Ag Respirable agglomerates of porous carrier particles and micronized drug
WO2015145353A1 (en) * 2014-03-27 2015-10-01 Novartis Ag Spray-dried solid-in-oil-in-water dispersions for inhalation of active pharmaceutical ingredients
PL3925607T5 (pl) 2014-04-15 2026-06-01 Vertex Pharmaceuticals Incorporated Kompozycje farmaceutyczne do leczenia chorób, w których pośredniczy mukowiscydozowy przezbłonowy regulator przewodnictwa
CA2963945C (en) 2014-10-07 2023-01-10 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
WO2016142708A2 (en) * 2015-03-10 2016-09-15 Cipla Limited Pharmaceutical composition
US10423736B2 (en) * 2015-08-28 2019-09-24 University Of British Columbia Methods and systems for simulating hydrodynamics in gas-solid fluidized beds
EP3335699A1 (en) 2016-12-15 2018-06-20 H e x a l Aktiengesellschaft Selexipag formulation in liquisolid system
CN106943350A (zh) * 2017-03-14 2017-07-14 上海现代药物制剂工程研究中心有限公司 含毒蕈碱受体拮抗剂和β2受体激动剂的气雾剂及制备方法
WO2019060595A1 (en) * 2017-09-20 2019-03-28 Teva Branded Pharmaceutical Products R&D, Inc. INHALABLE DRY POWDER MEDICINAL PRODUCT COMPRISING GLYCOPYRRONIUM
US20200324064A1 (en) * 2019-04-10 2020-10-15 Cai Gu Huang Inhalation Device for Administering Powdered Pharmaceutical Composition
WO2020247376A1 (en) * 2019-06-03 2020-12-10 Cai Gu Huang Inhalable formulation of a solution containing indacaterol maleate and glycopyrronium bromide
CN112137957B (zh) * 2019-06-26 2022-07-29 长风药业股份有限公司 一种药用吸入气雾剂及其制备方法
WO2021030307A1 (en) * 2019-08-15 2021-02-18 Abbott Laboratories Nutritional powder manufacturing process using micronization, and powder composition
CN115916173A (zh) * 2020-04-13 2023-04-04 巴塞尔大学医院 Lsd剂量鉴定
CN114344285B (zh) * 2020-10-14 2023-11-14 江苏恒瑞医药股份有限公司 改良的可吸入团聚物
TW202237102A (zh) * 2020-12-11 2022-10-01 大陸商江蘇恒瑞醫藥股份有限公司 用於肺部遞送的藥物組合物
CN113318097A (zh) * 2021-04-29 2021-08-31 珠海瑞思普利医药科技有限公司 一种抗特发性肺纤维化的粉雾剂及制备方法
EP4329759A4 (en) 2021-04-30 2025-07-16 Mind Medicine Inc CRYSTALLINE FORMS OF LSD SALTS
US20230064429A1 (en) 2021-08-19 2023-03-02 Mind Medicine, Inc. IMMEDIATE RELEASE FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS
CN116785239A (zh) * 2022-03-17 2023-09-22 上海惠永药物研究有限公司 喷雾冷冻干燥制备微球的方法
CN116785246B (zh) * 2022-03-17 2026-06-12 上海惠永药物研究有限公司 一种药物微球及含其的气雾剂
CN117357485B (zh) * 2023-11-01 2024-09-24 山东京卫制药有限公司 一种改良的可吸入的载体颗粒及应用
WO2025256638A1 (zh) * 2024-06-14 2025-12-18 上海济昀生物科技有限公司 一种混悬型三联吸入气雾剂组合物及其制备方法

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
IT1016489B (it) 1974-03-18 1977-05-30 Isf Spa Inalatore
CY1359A (en) 1981-02-02 1987-08-07 Schering Corp Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them
SE448277B (sv) 1985-04-12 1987-02-09 Draco Ab Indikeringsanordning vid en doseringsanordning for lekemedel
US6536427B2 (en) 1990-03-02 2003-03-25 Glaxo Group Limited Inhalation device
NZ243314A (en) 1991-06-26 1994-07-26 Schering Corp Powder dispenser; single metered dose rotated to dispensing conduit
JP2924924B2 (ja) 1992-12-18 1999-07-26 シェリング・コーポレーション 粉末薬物のための吸入器
US6794357B1 (en) * 1993-06-24 2004-09-21 Astrazeneca Ab Compositions for inhalation
US5837699A (en) 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
ATE387925T1 (de) 1994-09-21 2008-03-15 Nektar Therapeutics Vorrichtung und verfahren zum dispergieren von trockenen pulvermedikamenten
CN1213974A (zh) 1996-01-03 1999-04-14 葛兰素集团有限公司 吸入器具
DK0883415T3 (da) 1996-02-21 2002-08-19 Schering Corp Inhalator til pulverformigt medikament
SI0937041T1 (en) 1996-11-11 2003-10-31 Christian R. Noe Use of a pharmaceutically acceptable salt of (3R,2'R)-3-((Cyclopently-hydroxyphenylacetyl)oxy)-1,1-dimethyl-pyrrolidinium for the preparation of a medicament
US6613795B2 (en) 1996-11-11 2003-09-02 Christian Noe Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments
US6010935A (en) 1997-08-21 2000-01-04 Micron Technology, Inc. Self aligned contacts
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
UA73924C2 (en) 1998-10-09 2005-10-17 Nektar Therapeutics Device for delivering active agent formulation to lungs of human patient
CN1150895C (zh) 1998-11-13 2004-05-26 杰格研究股份公司 用于吸入给药的干粉
US20070212422A1 (en) 1999-11-10 2007-09-13 Manfred Keller Dry powder for inhalation
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
PT1181069E (pt) 1999-05-28 2006-11-30 Nektar Therapeutics Dispositivo e método para a administração de uma dose calibrada de medicamento em aerosol
US20010029947A1 (en) 1999-12-17 2001-10-18 Steve Paboojian Receptacles to facilitate the extraction of powders
US7069929B2 (en) 2000-02-01 2006-07-04 Quadrant Technologies Limited Dry powder inhaler
PT1280520E (pt) 2000-05-10 2014-12-16 Novartis Ag Pós à base de fosfolípidos para administração de fármacos
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
GB0201677D0 (en) 2002-01-25 2002-03-13 Glaxo Group Ltd Medicament dispenser
JP2006511617A (ja) 2002-12-13 2006-04-06 アダーギット 製薬用多孔質粒子
AU2004229446B2 (en) 2003-04-09 2010-02-25 Bgp Products Operations Gmbh Aerosolization apparatus with air inlet shield
GB0317374D0 (en) 2003-07-24 2003-08-27 Glaxo Group Ltd Medicament dispenser
GB2407042B (en) 2003-10-17 2007-10-24 Vectura Ltd Inhaler
PL1718353T3 (pl) 2004-02-24 2020-06-01 Microdose Therapeutx, Inc. Urządzenie do dostarczania leku na bazie strugi syntetycznej
GB0410712D0 (en) 2004-05-13 2004-06-16 Novartis Ag Organic compounds
GB0413960D0 (en) 2004-06-22 2004-07-28 Novartis Ag Organic compounds
ITMI20051999A1 (it) 2005-10-21 2007-04-22 Eratech S R L Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
GB0613161D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
US8198450B2 (en) 2006-06-30 2012-06-12 Novartis Ag Quinolinone derivatives and their pharmaceutical compositions
EP2668970B1 (en) 2006-10-25 2016-07-06 Novartis AG Powder dispersion apparatus
US8834930B2 (en) 2008-05-15 2014-09-16 Novartis Ag Pulmonary delivery of a fluoroquinolone
KR101290893B1 (ko) 2009-04-09 2013-07-29 노파르티스 아게 피롤리디늄 염의 제조 방법
US8815258B2 (en) * 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
WO2011120779A1 (en) 2010-04-01 2011-10-06 Chiesi Farmaceutici S.P.A. Process for preparing carrier particles for dry powders for inhalation
JOP20120023B1 (ar) * 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
US9452139B2 (en) * 2013-03-14 2016-09-27 Novartis Ag Respirable agglomerates of porous carrier particles and micronized drug

Also Published As

Publication number Publication date
EA201591729A1 (ru) 2016-05-31
EP2968570A1 (en) 2016-01-20
US9744178B2 (en) 2017-08-29
AU2017203258A1 (en) 2017-06-08
SA515361055B1 (ar) 2016-11-13
AU2017203258B2 (en) 2019-06-20
MX2015012814A (es) 2016-02-03
AU2014229265A1 (en) 2015-09-03
JP6374414B2 (ja) 2018-08-15
IL240963A (en) 2017-05-29
PH12015501882A1 (en) 2015-12-07
BR112015021814A2 (pt) 2017-07-18
GT201500295A (es) 2017-09-28
US20160354388A1 (en) 2016-12-08
CN105188757B (zh) 2019-04-30
CN105188757A (zh) 2015-12-23
US20140302147A1 (en) 2014-10-09
SG11201506397QA (en) 2015-09-29
CL2015002632A1 (es) 2016-03-28
US9452139B2 (en) 2016-09-27
WO2014141135A1 (en) 2014-09-18
PE20151655A1 (es) 2015-11-26
IL240963A0 (en) 2015-11-30
CA2905615A1 (en) 2014-09-18
TN2015000395A1 (en) 2017-01-03
JP2016512494A (ja) 2016-04-28
HK1212616A1 (zh) 2016-06-17
KR20150129716A (ko) 2015-11-20
MA38397A1 (fr) 2018-01-31

Similar Documents

Publication Publication Date Title
IL240963A0 (en) Respirable agglomerates of airborne carrier particles and miniaturized drugs
IL236666B (en) Systems and methods for delivering a drug as a dry powder
IL240291A0 (en) History of pyridazinone and pharmaceutical preparations containing them
EP3052551A4 (en) Benefit agent containing delivery particle
SG11201600028YA (en) Substituted aminopyrimidine compounds and methods of use
EP3063982A4 (en) User equipment and methods of bearer operation for carrier aggregation
SG11201510179PA (en) Amino-triazine derivatives and pharmaceutical composition containing said derivatives
SG10201705895TA (en) Microdevices for separation of non-spherical particles and applications thereof
IL246145A0 (en) Surface treatment of particles and their use
EP3053937A4 (en) Modified polytetrafluoroethylene fine powder and uniaxially oriented porous body
PT2976072T (pt) Partículas finas de epinefrina e métodos de utilização das mesmas para o tratamento de afeções que reagem à epinefrina
PT3613421T (pt) Ácido acetilsalicílico para reduzir o risco de um evento tromboembólico
EP2964261A4 (en) STABILIZATION OF MOISTURE-SENSITIVE DRUGS
EP3006106A4 (en) Catalyst particles, loaded catalyst particles, and use of same
IL244496A0 (en) Synthesis and particle engineering of co-crystals
PT2994150T (pt) Probióticos e métodos de utilização
IL240505A0 (en) Accumulations of lanthanides and methods for their use
GB201806558D0 (en) Superfically porous particles with precisely controlled particle density and methods of preparation and use thereof
IL240292A0 (en) History of quinazoline and pharmaceutical preparations containing them
IL276838B (en) Oral formulation and suspension of an oncology drug
ZA201507706B (en) Inhalable pharmaceutical compositions and the inhaler devices containing them
SG11201506728PA (en) Overcoated powder particles
GB201307082D0 (en) Pharmaceutical composition comprising 15-HETrE and methods of using the same
GB201307659D0 (en) Preparation of drug particles by micronisation
GB201415815D0 (en) Size reduction device and method for the size reduction of solid particles